Decision-Making on New Non-Drug Health Technologies by Hospitals and Health Authorities in Canada.


Journal

Healthcare policy = Politiques de sante
ISSN: 1715-6580
Titre abrégé: Healthc Policy
Pays: Canada
ID NLM: 101280107

Informations de publication

Date de publication:
08 2019
Historique:
entrez: 21 10 2019
pubmed: 21 10 2019
medline: 8 9 2020
Statut: ppublish

Résumé

Unlike those for publicly funded drugs in Canada, coverage decision-making processes for non-drug health technologies (NDTs) are not well understood. This paper aims to describe existing NDT decision-making processes in different healthcare organizations across Canada. A self-administered survey was used to determine demographic and financial characteristics of organizations, followed by in-depth interviews with senior leadership of consenting organizations to understand the processes for making funding decisions on NDTs. Seventy-three and 48 organizations completed self-administered surveys and telephone interviews, respectively (with 45 participating in both ways). Fifty-five different processes were identified, the majority of which addressed capital equipment. Most involved multidisciplinary committees (with medical and non-medical representation), but the types of information used to inform deliberations varied. Across all processes, decision-making criteria included local considerations such as alignment with organizational priorities. NDT decision-making processes vary in complexity, depending on characteristics of the healthcare organization and context.

Identifiants

pubmed: 31629458
pii: hcpol.2019.25936
doi: 10.12927/hcpol.2019.25936
pmc: PMC7008692
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-94

Informations de copyright

Copyright © 2019 Longwoods Publishing.

Références

CMAJ. 1992 Feb 15;146(4):461-2
pubmed: 1737310
Healthc Manage Forum. 1994 Winter;7(4):18-27
pubmed: 10140164
Value Health. 2009 Jun;12 Suppl 2:S14-9
pubmed: 19523180
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:53-60
pubmed: 19527534
CMAJ. 2015 Jan 6;187(1):E19-E20
pubmed: 25114286

Auteurs

Tania Stafinski (T)

School of Public Health, University of Alberta, Edmonton, AB.

Raisa Deber (R)

Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON.

Marc Rhainds (M)

Unité d'évaluation des technologies et des modes d'intervention en santé , CHU de Québec - Université Laval, Laval, QC.

Janet Martin (J)

Director, Centre for Medical Evidence, Decision Integrity & Clinical Impact, Schulich School of Medicine & Dentistry, Western University, London, ON.

Tom Noseworthy (T)

Department of Community Health Sciences and Institute for Public Health, University of Calgary, Calgary, AB.

Stirling Bryan (S)

Centre for Clinical Epidemiology & Evaluation, University of British Columbia, Vancouver, BC.

Devidas Menon (D)

School of Public Health, University of Alberta, Edmonton, AB.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH